Propanc Biopharma Enters Material Definitive Agreement

TL;DR

Propanc Biopharma signed a big deal on Oct 7th, filing today.

AI Summary

Propanc Biopharma, Inc. entered into a material definitive agreement on October 7, 2025. The company, incorporated in Delaware with its principal executive office in Camberwell, Victoria, Australia, filed this 8-K report on October 14, 2025. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates a significant new contract or partnership for Propanc Biopharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can be a significant event, but the specifics of the agreement are not detailed in this initial filing, requiring further investigation.

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Registrant
• October 7, 2025 (date) — Date of earliest event reported
• October 14, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• Camberwell, Victoria, Australia (location) — Principal executive office address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PPCB The Nasdaq Stock Market LLC
• $5.00 — e lesser of a fixed conversion price of $5.00 per share or 85% of the of the lowest t

Filing Documents

• form8-k.htm (8-K) — 38KB
• ex10-1.htm (EX-10.1) — 360KB
• ex10-2.htm (EX-10.2) — 100KB
• 0001493152-25-018054.txt ( ) — 756KB
• ppcb-20251007.xsd (EX-101.SCH) — 3KB
• ppcb-20251007_lab.xml (EX-101.LAB) — 33KB
• ppcb-20251007_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 7, 2025, Propanc Biopharma., Inc. (the " Company ") entered into a Securities Purchase Agreement (the "SPA") with Hexstone Capital LLC ("Hexstone") in connection with a private placement of a to be created class Series C Preferred Stock ("Series C Preferred Stock"). Each share of Series C Preferred Stock shall be convertible into shares of common stock of the Company at a price equal to the lesser of a fixed conversion price of $5.00 per share or 85% of the of the lowest trading price of the Common Stock during the period beginning on the day the holder sends a conversion notice to the Company and ending on the trading day on which the aggregate dollar volume of the Company's common stock exceeds the product of the conversion amount set forth on the applicable conversion notice multiplied by seven (7) after the applicable holder receives the shares of common stock issuable upon conversion of the Series C Preferred Stock, subject to a five (5) trading day minimum. Pursuant to the SPA, at the Closing, the Company shall issue 100 shares of Series C Preferred Stock and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock (the Warrant"). Certain conditions to close exist, including the filing of a Certificate of Designation of the Series C Preferred Stock with the Delaware Secretary of State. The foregoing descriptions of the SPA and Warrant do not purport to be complete and are qualified in their entirety by reference to the full text of the SPA and Warrant, which are attached hereto as Exhibit 10.1 , and Exhibit 10.2 , and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 Securities Purchase Agreement dated October 7, 2025, by and between Propanc Biopharma, Inc. and Hexstone Capital LLC 10.2 Warrant Agreement dated October 7, 2025 104 Cover Page Interactive Data File (embedded with

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR